NCT01258686已完成3 期
A Double-blind Phase III Study With Silymarin in the Patients Infected With HCV Who Failed Conventional Antiviral Therapy
Bukwang Pharmaceutical1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2010年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 53
- 试验地点
- 1
- 主要终点
- The proportion of patient with serum ALT less than or equal to 40 IU/L or achieves at least 50% decline to less than 60 IU/L
研究概览
简要总结
The purpose of this study is to determine the effectiveness of silymarin 700 mg thrice daily and assess the safety in patients with hepatitis C virus infection compared to a placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at least 18 years at screening.
- •Serum HCV RNA above quantifiable level of detection after the end of previous therapy.
- •ALT > 60 IU/L (i.e., approximately 1.5 X upper limit of normal) obtained during the screening period.
- •Previous treatment with any interferon-based therapy but 1) without sustained virological response or 2) HCV RNA detected at the end of the treatment or 3) HCV RNA undetected during the treatment and detected after or 4) have partial response(HCV RNA < 2log10 but is not eradicated) or 5) have no response or 6) discontinuation due to side effect
- •Negative urine pregnancy test (for women of childbearing potential). Females of childbearing potential must be using effective contraception during the study.
排除标准
- •ALT ≥ 10*ULN(Upper Limit of Normal) at the screening
- •Use of silymarin or other milk thistle preparations within 30 days prior to screening.
- •Use of other antioxidants such as vitamin E, vitamin C, glutathione, alpha-tocopherol, or non-prescribed complementary alternative medications (including dietary supplements, megadose vitamins, herbal preparations, and special teas) within 30 days prior to screening. A multivitamin at standard doses will be allowed.
- •Use of silymarin or other antioxidants or non-prescribed complementary alternative medications (as above) during the screening period or patient unwilling to refrain from taking these medications through completion of the study.
- •Any antiviral therapy within 6 months prior to screening visit.
- •Known allergy/sensitivity to milk thistle or its preparations.
- •Evidence of poorly-controlled diabetes (defined as HbA1c > 8% in patients with diabetes).
- •Use of warfarin, metronidazole or acetaminophen (greater than two grams per day) within 30 days of screening.
- •Previous Radiology test(Ultrasonography, Computed tomography,Magnetic Resonance Imaging) or liver biopsy that demonstrated presence of moderate to severe steatosis or evidence of steatohepatitis.
- •Positive test for anti-HIV or HBsAg within 5 years of screening.
- •Average alcohol consumption of more than one drink or equivalent (>12 grams) per day or more than two (2) drinks on any one day over the 30 days prior to screening. Patients who met either criterion more than 30 days ago must have consumed a monthly average of 12 grams or less per day of alcohol for at least six months prior to screening.
- •History of other chronic liver disease, including metabolic diseases, documented by appropriate test(s).
- •Women with ongoing pregnancy or breast-feeding, or contemplating pregnancy.
- •Serum creatinine level 2.0 mg/dL or greater at screening or CrCl ≤ 60cc/min, or currently on dialysis. The creatinine clearance (CrCl) will be calculated according to Cockcroft-Gault.
- •Evidence of drug abuse within 6 months prior to screening or during the screening period.
- •Evidence of decompensated liver disease defined as any of the following: serum albumin <3.2 g/dl, total bilirubin > 2.0 mg/dl, or PT/INR > 1.3 times normal at screening, or history or presence of ascites or encephalopathy, or bleeding from esophageal varices.
- •History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, coronary artery disease, or active gastrointestinal conditions that might interfere with drug absorption).
- •History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hepatitis, autoimmune hemolytic anemia, severe psoriasis, rheumatoid arthritis) that could affect inflammatory biomarkers.
- •History of solid organ or bone marrow transplantation.
- •History of thyroid disease poorly controlled on prescribed medications.
- •Use of oral steroids for more than 14 days within 30 days prior to screening.
- •Participation in a research drug trial within 6 months of enrollment.
- •Inability or unwillingness to provide informed consent or abide by the study protocol.
研究组 & 干预措施
placebo
Placebo Comparator
干预措施: Placebo (Drug)
silymarin, treatment
Experimental
干预措施: Silymarin (Drug)
结局指标
主要结局
The proportion of patient with serum ALT less than or equal to 40 IU/L or achieves at least 50% decline to less than 60 IU/L
时间窗: at week 24
次要结局
- the change from baseline in ALT and HCV RNA (log10)(36 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Silymarin in multiple SclerosisTherapeutic effect of silymarin.IRCT20171220037977N1Esfahan University of Medical Sciences60
已完成
2 期
To evaluate the effectiveness of Silymarin (Livergol) on IL-6 levels and size of endometrioma lesionsIRCT20150905023897N5Vice chancellor for research Tarbiat Modares University60
尚未招募
3 期
Effect of silymarin in inflammatory bowel diseaseK50-K52Inflammatory Bowel Disease.Noninfective inflammatory bowel diseaseIRCT20101107005123N3Mashhad University of Medical Sciences40
已完成
3 期
18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PDParkinson's DiseaseNCT01286935Newron Pharmaceuticals SPA544
已完成
4 期
A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 DiabetesType 2 Diabetes MellitusNCT00240253AstraZeneca200